CG Oncology, Inc. (CGON)
Health Care ยท Biological Products, (No Diagnostic Substances)
CG Oncology, Inc. (CGON) is listed on Nasdaq, where its shares have traded since January 25, 2024. SentiSense covers CG Oncology, Inc. in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances). Arthur Kuan is its chief executive officer. The company reports 142 employees, and its corporate website is www.cgoncology.com.
About CG Oncology, Inc.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Latest reported results
CG Oncology reported revenue of $1.6 million for Q3 FY2026, down 3.7% from the same period a year earlier.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 218 institutions reported holding CGON, with 93.7 million shares worth $6.7 billion in aggregate. The largest reported holders were T. Rowe Price, Rtw Investments and Vanguard. Of the 5 largest reported holders, 4 added shares and 1 held its position unchanged during the quarter.
More on CGON
- CGON sentiment: whether news and social coverage of CG Oncology, Inc. leans bullish or bearish, and the stories driving it.
- CGON ownership: all 218 reporting institutions, plus insider and congressional trades.
- CGON financials: revenue, net income, operating margin and free cash flow through Q3 FY2026.
SentiSense also tracks daily options readings for CG Oncology, Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does CG Oncology, Inc. do?
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer.
What sector is CGON in?
SentiSense classifies CG Oncology, Inc. in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances).
Where does CGON stock trade?
CG Oncology, Inc. (CGON) is listed on Nasdaq, where its shares have traded since January 25, 2024.
Who is the CEO of CG Oncology, Inc.?
Arthur Kuan is the chief executive officer of CG Oncology, Inc..